InMed Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $2,057,800 | $659,848 | $1,125 |
Gross Profit | -221 | 306,938 | -134 | 35 |
EBITDA | -1,789 | -2,950 | -2,658 | -2,624 |
EBIT | -2,010 | -3,211 | -2,791 | -2,782 |
Net Income | -2,330 | -5,084 | -2,966 | -2,782 |
Net Change In Cash | 0 | 2,057,800 | 659,848 | 1,125 |
Free Cash Flow | -1,142,342 | -2,909 | -1,758 | -3,226 |
Cash | 1,094,488 | 2,194 | 5,158 | 9,545 |
Basic Shares | 546 | 437 | 404 | 395 |
Annual Financials
| Values in thousands | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
Revenue | $3,176,496 | $4,942 | $4,597 | $4,135 |
Gross Profit | 709,843 | 1,706 | 1,100 | 1,403 |
EBITDA | -9,186 | -7,255 | -7,063 | -7,338 |
EBIT | -9,895 | -7,790 | -7,668 | -7,934 |
Net Income | -12,560 | -8,162 | -7,675 | -7,947 |
Net Change In Cash | 3,176,496 | 4,942 | 4,597 | 4,135 |
Free Cash Flow | -8,643,513 | -7,766 | -6,995 | -7,445 |
Cash | 2,194 | 15,090 | 8,987 | 11,806 |
Basic Shares | 416 | 97 | 38 | 12 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.36 |
2026-06-30 | -$1.43 |
2026-03-31 | -$0.73 |
2025-12-31 | -$0.51 |